Blueprint Medicines Corp Earnings

Blueprint Medicines Corp’s revenue jumped 55.45% since last year same period to $149.41Mn in the Q1 2025. On a quarterly growth basis, Blueprint Medicines Corp has generated 2.08% jump in its revenue since last 3-months.

Blueprint Medicines Corp’s net profit fell -99.44% since last year same period to $0.5Mn in the Q1 2025. On a quarterly growth basis, Blueprint Medicines Corp has generated 100.99% jump in its net profits since last 3-months.

Blueprint Medicines Corp’s net profit margin fell -99.64% since last year same period to 0.33% in the Q1 2025. On a quarterly growth basis, Blueprint Medicines Corp has generated 100.97% jump in its net profit margins since last 3-months.

Blueprint Medicines Corp’s earning per share (EPS) estimates for the current quarter stand at -1.66 - a -132.46% fall from last quarter’s estimates.

Blueprint Medicines Corp’s earning per share (EPS) estimates for the current year stand at -1.66.

Blueprint Medicines Corp’s earning per share (EPS) fell -120.97% since last year same period to -0.29 in the Q1 2025. This indicates that the Blueprint Medicines Corp has generated -120.97% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Blueprint Medicines Corp’s return on assets (ROA) stands at -0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Blueprint Medicines Corp’s return on equity (ROE) stands at -0.48.